Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

2.

Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia.

Ballantyne CM, Neutel J, Cropp A, Duggan W, Wang EQ, Plowchalk D, Sweeney K, Kaila N, Vincent J, Bays H.

Am J Cardiol. 2015 May 1;115(9):1212-21. doi: 10.1016/j.amjcard.2015.02.006. Epub 2015 Feb 12.

3.

Novel, selective vitamin D analog suppresses parathyroid hormone in uremic animals and postmenopausal women.

Zella JB, Plum LA, Plowchalk DR, Potochoiba M, Clagett-Dame M, DeLuca HF.

Am J Nephrol. 2014;39(6):476-83. doi: 10.1159/000362846. Epub 2014 May 17.

4.

Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug.

Vieira ML, Kirby B, Ragueneau-Majlessi I, Galetin A, Chien JY, Einolf HJ, Fahmi OA, Fischer V, Fretland A, Grime K, Hall SD, Higgs R, Plowchalk D, Riley R, Seibert E, Skordos K, Snoeys J, Venkatakrishnan K, Waterhouse T, Obach RS, Berglund EG, Zhang L, Zhao P, Reynolds KS, Huang SM.

Clin Pharmacol Ther. 2014 Feb;95(2):189-98. doi: 10.1038/clpt.2013.187. Epub 2013 Sep 18.

PMID:
24048277
5.

Drug metabolites as cytochrome p450 inhibitors: a retrospective analysis and proposed algorithm for evaluation of the pharmacokinetic interaction potential of metabolites in drug discovery and development.

Callegari E, Kalgutkar AS, Leung L, Obach RS, Plowchalk DR, Tse S.

Drug Metab Dispos. 2013 Dec;41(12):2047-55. doi: 10.1124/dmd.113.052241. Epub 2013 Jun 21.

PMID:
23792812
6.

Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2.

Plowchalk DR, Rowland Yeo K.

Eur J Clin Pharmacol. 2012 Jun;68(6):951-60. doi: 10.1007/s00228-011-1189-y. Epub 2012 Jan 19.

PMID:
22258279
7.

Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling.

Jones HM, Gardner IB, Collard WT, Stanley PJ, Oxley P, Hosea NA, Plowchalk D, Gernhardt S, Lin J, Dickins M, Rahavendran SR, Jones BC, Watson KJ, Pertinez H, Kumar V, Cole S.

Clin Pharmacokinet. 2011 May;50(5):331-47. doi: 10.2165/11539680-000000000-00000.

PMID:
21456633
8.

Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction.

Fahmi OA, Hurst S, Plowchalk D, Cook J, Guo F, Youdim K, Dickins M, Phipps A, Darekar A, Hyland R, Obach RS.

Drug Metab Dispos. 2009 Aug;37(8):1658-66. doi: 10.1124/dmd.108.026252. Epub 2009 Apr 30.

PMID:
19406954
9.

Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction.

Youdim KA, Zayed A, Dickins M, Phipps A, Griffiths M, Darekar A, Hyland R, Fahmi O, Hurst S, Plowchalk DR, Cook J, Guo F, Obach RS.

Br J Clin Pharmacol. 2008 May;65(5):680-92. doi: 10.1111/j.1365-2125.2007.03070.x. Epub 2008 Feb 14.

10.

The sulfonylurea glipizide does not inhibit ischemic preconditioning in anesthetized rabbits.

Flynn DM, Smith AH, Treadway JL, Levy CB, Soeller WC, Boettner WA, Wisniecki P, Plowchalk DR, Gernhardt SS, Tracey WR, Knight DR.

Cardiovasc Drugs Ther. 2005 Oct;19(5):337-46.

PMID:
16382296
11.

An EP2 receptor-selective prostaglandin E2 agonist induces bone healing.

Paralkar VM, Borovecki F, Ke HZ, Cameron KO, Lefker B, Grasser WA, Owen TA, Li M, DaSilva-Jardine P, Zhou M, Dunn RL, Dumont F, Korsmeyer R, Krasney P, Brown TA, Plowchalk D, Vukicevic S, Thompson DD.

Proc Natl Acad Sci U S A. 2003 May 27;100(11):6736-40. Epub 2003 May 14.

13.

Mode-of-action-based dosimeters for interspecies extrapolation of vinyl acetate inhalation risk.

Bogdanffy MS, Plowchalk DR, Sarangapani R, Starr TB, Andersen ME.

Inhal Toxicol. 2001 May;13(5):377-96. Review.

PMID:
11295869
14.

Role of prolactin in chloro-S-triazine rat mammary tumorigenesis.

O'Connor JC, Plowchalk DR, Van Pelt CS, Davis LG, Cook JC.

Drug Chem Toxicol. 2000 Nov;23(4):575-601.

PMID:
11071396
15.

A biologically based risk assessment for vinyl acetate-induced cancer and noncancer inhalation toxicity.

Bogdanffy MS, Sarangapani R, Plowchalk DR, Jarabek A, Andersen ME.

Toxicol Sci. 1999 Sep;51(1):19-35.

PMID:
10496674
16.

Analysis of vinyl acetate metabolism in rat and human nasal tissues by an in vitro gas uptake technique.

Bogdanffy MS, Sarangapani R, Kimbell JS, Frame SR, Plowchalk DR.

Toxicol Sci. 1998 Dec;46(2):235-46.

PMID:
10048126
17.

Physiologically based modeling of vinyl acetate uptake, metabolism, and intracellular pH changes in the rat nasal cavity.

Plowchalk DR, Andersen ME, Bogdanffy MS.

Toxicol Appl Pharmacol. 1997 Feb;142(2):386-400.

PMID:
9070362
18.

A physiologically based pharmacokinetic model for nicotine disposition in the Sprague-Dawley rat.

Plowchalk DR, Andersen ME, deBethizy JD.

Toxicol Appl Pharmacol. 1992 Oct;116(2):177-88.

PMID:
1412462
19.

The effect of benzo(a)pyrene on murine ovarian and corpora lutea volumes.

Miller MM, Plowchalk DR, Weitzman GA, London SN, Mattison DR.

Am J Obstet Gynecol. 1992 May;166(5):1535-41.

PMID:
1595809
20.

Reproductive toxicity of cyclophosphamide in the C57BL/6N mouse: 2. Effects on uterine structure and function.

Plowchalk DR, Meadows MJ, Mattison DR.

Reprod Toxicol. 1992;6(5):423-9.

PMID:
1463922
21.
22.

The nitrosation of nicotine: a kinetic study.

Caldwell WS, Greene JM, Plowchalk DR, deBethizy JD.

Chem Res Toxicol. 1991 Sep-Oct;4(5):513-6. No abstract available.

PMID:
1793797
23.

Phosphoramide mustard is responsible for the ovarian toxicity of cyclophosphamide.

Plowchalk DR, Mattison DR.

Toxicol Appl Pharmacol. 1991 Mar 1;107(3):472-81.

PMID:
2000634
24.

Comparison of random and serial sections in assessment of ovarian toxicity.

Smith BJ, Plowchalk DR, Sipes IG, Mattison DR.

Reprod Toxicol. 1991;5(4):379-83.

PMID:
1806143
25.

Reproductive toxicity: male and female reproductive systems as targets for chemical injury.

Mattison DR, Plowchalk DR, Meadows MJ, al-Juburi AZ, Gandy J, Malek A.

Med Clin North Am. 1990 Mar;74(2):391-411. Review.

PMID:
2181211
26.

Effects of manganese (Mn++) and iron (Fe+++) on magnetic resonance imaging (MRI) characteristics of human placenta and amniotic fluid.

Plowchalk DR, Jordan JP, Thomford PJ, Mattison DR.

Physiol Chem Phys Med NMR. 1987;19(1):35-41.

PMID:
3615643

Supplemental Content

Loading ...
Support Center